nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—SLC6A3—malignant glioma	0.668	1	CbGaD
Escitalopram—HTR2C—choroid plexus—malignant glioma	0.0196	0.291	CbGeAlD
Escitalopram—SLC6A3—telencephalic ventricle—malignant glioma	0.00595	0.0881	CbGeAlD
Escitalopram—HTR2C—telencephalic ventricle—malignant glioma	0.00575	0.0852	CbGeAlD
Escitalopram—Citalopram—CYP2B6—malignant glioma	0.00447	0.54	CrCbGaD
Escitalopram—CYP3A4—Temozolomide—malignant glioma	0.00383	1	CbGbCtD
Escitalopram—Citalopram—SLC6A3—malignant glioma	0.00381	0.46	CrCbGaD
Escitalopram—SLC6A3—brainstem—malignant glioma	0.00161	0.0238	CbGeAlD
Escitalopram—HTR2C—brainstem—malignant glioma	0.00156	0.023	CbGeAlD
Escitalopram—SLC6A4—brainstem—malignant glioma	0.00148	0.0218	CbGeAlD
Escitalopram—SLC6A3—telencephalon—malignant glioma	0.00143	0.0212	CbGeAlD
Escitalopram—HTR2C—telencephalon—malignant glioma	0.00138	0.0205	CbGeAlD
Escitalopram—SLC6A4—telencephalon—malignant glioma	0.00131	0.0194	CbGeAlD
Escitalopram—CHRM1—telencephalon—malignant glioma	0.0013	0.0193	CbGeAlD
Escitalopram—SLC6A2—brainstem—malignant glioma	0.0013	0.0192	CbGeAlD
Escitalopram—ADRA1A—brainstem—malignant glioma	0.00121	0.0179	CbGeAlD
Escitalopram—SLC6A2—telencephalon—malignant glioma	0.00115	0.0171	CbGeAlD
Escitalopram—HTR2C—medulla oblongata—malignant glioma	0.00109	0.0161	CbGeAlD
Escitalopram—ADRA1A—telencephalon—malignant glioma	0.00107	0.0159	CbGeAlD
Escitalopram—SLC6A3—midbrain—malignant glioma	0.00103	0.0152	CbGeAlD
Escitalopram—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00101	0.00519	CcSEcCtD
Escitalopram—Endocrine disorder—Temozolomide—malignant glioma	0.00101	0.00515	CcSEcCtD
Escitalopram—Speech disorder—Carmustine—malignant glioma	0.001	0.00514	CcSEcCtD
Escitalopram—SLC6A3—spinal cord—malignant glioma	0.001	0.0148	CbGeAlD
Escitalopram—HTR2C—midbrain—malignant glioma	0.000992	0.0147	CbGeAlD
Escitalopram—Accidental injury—Carmustine—malignant glioma	0.000976	0.005	CcSEcCtD
Escitalopram—Speech disorder—Temozolomide—malignant glioma	0.00097	0.00497	CcSEcCtD
Escitalopram—HTR2C—spinal cord—malignant glioma	0.000968	0.0143	CbGeAlD
Escitalopram—Disturbance in attention—Temozolomide—malignant glioma	0.000963	0.00493	CcSEcCtD
Escitalopram—Breast pain—Temozolomide—malignant glioma	0.000957	0.0049	CcSEcCtD
Escitalopram—Amenorrhoea—Temozolomide—malignant glioma	0.00095	0.00486	CcSEcCtD
Escitalopram—Thinking abnormal—Carmustine—malignant glioma	0.000943	0.00483	CcSEcCtD
Escitalopram—SLC6A4—midbrain—malignant glioma	0.000941	0.0139	CbGeAlD
Escitalopram—Drug interaction—Carmustine—malignant glioma	0.000931	0.00476	CcSEcCtD
Escitalopram—Viral infection—Temozolomide—malignant glioma	0.000924	0.00473	CcSEcCtD
Escitalopram—Leukocytosis—Carmustine—malignant glioma	0.000919	0.0047	CcSEcCtD
Escitalopram—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000918	0.0047	CcSEcCtD
Escitalopram—SLC6A4—spinal cord—malignant glioma	0.000918	0.0136	CbGeAlD
Escitalopram—SLC6A2—medulla oblongata—malignant glioma	0.000906	0.0134	CbGeAlD
Escitalopram—Herpes simplex—Temozolomide—malignant glioma	0.000906	0.00463	CcSEcCtD
Escitalopram—Gait disturbance—Carmustine—malignant glioma	0.000885	0.00453	CcSEcCtD
Escitalopram—Hepatic enzyme increased—Temozolomide—malignant glioma	0.000882	0.00452	CcSEcCtD
Escitalopram—Coordination abnormal—Carmustine—malignant glioma	0.000879	0.0045	CcSEcCtD
Escitalopram—Neck pain—Carmustine—malignant glioma	0.000874	0.00447	CcSEcCtD
Escitalopram—Pulmonary embolism—Carmustine—malignant glioma	0.000864	0.00442	CcSEcCtD
Escitalopram—Gait disturbance—Temozolomide—malignant glioma	0.000855	0.00438	CcSEcCtD
Escitalopram—Coordination abnormal—Temozolomide—malignant glioma	0.00085	0.00435	CcSEcCtD
Escitalopram—Musculoskeletal pain—Temozolomide—malignant glioma	0.000845	0.00432	CcSEcCtD
Escitalopram—Pulmonary embolism—Temozolomide—malignant glioma	0.000835	0.00427	CcSEcCtD
Escitalopram—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000835	0.00427	CcSEcCtD
Escitalopram—Vaginal inflammation—Temozolomide—malignant glioma	0.000835	0.00427	CcSEcCtD
Escitalopram—Urinary incontinence—Carmustine—malignant glioma	0.000834	0.00427	CcSEcCtD
Escitalopram—Depressed level of consciousness—Carmustine—malignant glioma	0.000834	0.00427	CcSEcCtD
Escitalopram—HRH1—telencephalon—malignant glioma	0.00083	0.0123	CbGeAlD
Escitalopram—Candida infection—Carmustine—malignant glioma	0.000825	0.00422	CcSEcCtD
Escitalopram—SLC6A3—central nervous system—malignant glioma	0.000812	0.012	CbGeAlD
Escitalopram—Neuropathy—Carmustine—malignant glioma	0.000811	0.00415	CcSEcCtD
Escitalopram—Influenza like illness—Temozolomide—malignant glioma	0.000811	0.00415	CcSEcCtD
Escitalopram—Depressed level of consciousness—Temozolomide—malignant glioma	0.000806	0.00412	CcSEcCtD
Escitalopram—Urinary incontinence—Temozolomide—malignant glioma	0.000806	0.00412	CcSEcCtD
Escitalopram—Candida infection—Temozolomide—malignant glioma	0.000797	0.00408	CcSEcCtD
Escitalopram—SLC6A3—cerebellum—malignant glioma	0.000794	0.0118	CbGeAlD
Escitalopram—Coma—Carmustine—malignant glioma	0.000789	0.00404	CcSEcCtD
Escitalopram—Vaginal infection—Temozolomide—malignant glioma	0.000788	0.00403	CcSEcCtD
Escitalopram—HTR2C—central nervous system—malignant glioma	0.000785	0.0116	CbGeAlD
Escitalopram—Aplastic anaemia—Temozolomide—malignant glioma	0.000784	0.00401	CcSEcCtD
Escitalopram—Neuropathy—Temozolomide—malignant glioma	0.000784	0.00401	CcSEcCtD
Escitalopram—Neoplasm—Carmustine—malignant glioma	0.000781	0.004	CcSEcCtD
Escitalopram—Gynaecomastia—Carmustine—malignant glioma	0.000773	0.00395	CcSEcCtD
Escitalopram—Dry eye—Temozolomide—malignant glioma	0.000771	0.00395	CcSEcCtD
Escitalopram—Neoplasm—Temozolomide—malignant glioma	0.000755	0.00386	CcSEcCtD
Escitalopram—Abnormal vision—Carmustine—malignant glioma	0.000753	0.00385	CcSEcCtD
Escitalopram—Mental disability—Carmustine—malignant glioma	0.000749	0.00384	CcSEcCtD
Escitalopram—Sepsis—Carmustine—malignant glioma	0.000749	0.00384	CcSEcCtD
Escitalopram—SLC6A4—central nervous system—malignant glioma	0.000744	0.011	CbGeAlD
Escitalopram—CHRM1—central nervous system—malignant glioma	0.000742	0.011	CbGeAlD
Escitalopram—Abnormal vision—Temozolomide—malignant glioma	0.000728	0.00373	CcSEcCtD
Escitalopram—Phlebitis—Carmustine—malignant glioma	0.000728	0.00372	CcSEcCtD
Escitalopram—Mental disability—Temozolomide—malignant glioma	0.000724	0.00371	CcSEcCtD
Escitalopram—Diabetes mellitus—Carmustine—malignant glioma	0.000721	0.00369	CcSEcCtD
Escitalopram—CYP2D6—brainstem—malignant glioma	0.000711	0.0105	CbGeAlD
Escitalopram—Ear pain—Temozolomide—malignant glioma	0.00071	0.00363	CcSEcCtD
Escitalopram—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000697	0.00356	CcSEcCtD
Escitalopram—Eye pain—Carmustine—malignant glioma	0.000694	0.00355	CcSEcCtD
Escitalopram—Gastroenteritis—Temozolomide—malignant glioma	0.000684	0.0035	CcSEcCtD
Escitalopram—Injury—Carmustine—malignant glioma	0.000682	0.00349	CcSEcCtD
Escitalopram—Deafness—Temozolomide—malignant glioma	0.000677	0.00347	CcSEcCtD
Escitalopram—Vascular purpura—Temozolomide—malignant glioma	0.000677	0.00347	CcSEcCtD
Escitalopram—Hepatic failure—Temozolomide—malignant glioma	0.000674	0.00345	CcSEcCtD
Escitalopram—Eye pain—Temozolomide—malignant glioma	0.000671	0.00343	CcSEcCtD
Escitalopram—Amnesia—Carmustine—malignant glioma	0.000667	0.00342	CcSEcCtD
Escitalopram—Nasal congestion—Temozolomide—malignant glioma	0.000665	0.0034	CcSEcCtD
Escitalopram—SLC6A2—central nervous system—malignant glioma	0.000655	0.0097	CbGeAlD
Escitalopram—Hot flush—Temozolomide—malignant glioma	0.000648	0.00331	CcSEcCtD
Escitalopram—SLC6A3—brain—malignant glioma	0.000645	0.00955	CbGeAlD
Escitalopram—Amnesia—Temozolomide—malignant glioma	0.000645	0.0033	CcSEcCtD
Escitalopram—Menopausal symptoms—Temozolomide—malignant glioma	0.000642	0.00329	CcSEcCtD
Escitalopram—Thirst—Temozolomide—malignant glioma	0.000637	0.00326	CcSEcCtD
Escitalopram—CYP2D6—telencephalon—malignant glioma	0.000631	0.00935	CbGeAlD
Escitalopram—Hyponatraemia—Carmustine—malignant glioma	0.000629	0.00322	CcSEcCtD
Escitalopram—Purpura—Temozolomide—malignant glioma	0.000629	0.00322	CcSEcCtD
Escitalopram—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000627	0.00321	CcSEcCtD
Escitalopram—Diplopia—Carmustine—malignant glioma	0.000627	0.00321	CcSEcCtD
Escitalopram—HTR2C—brain—malignant glioma	0.000623	0.00923	CbGeAlD
Escitalopram—ADRA1A—central nervous system—malignant glioma	0.000609	0.00902	CbGeAlD
Escitalopram—Diplopia—Temozolomide—malignant glioma	0.000606	0.0031	CcSEcCtD
Escitalopram—Face oedema—Carmustine—malignant glioma	0.000605	0.0031	CcSEcCtD
Escitalopram—Affect lability—Temozolomide—malignant glioma	0.000596	0.00305	CcSEcCtD
Escitalopram—ADRA1A—cerebellum—malignant glioma	0.000596	0.00882	CbGeAlD
Escitalopram—SLC6A4—brain—malignant glioma	0.000591	0.00875	CbGeAlD
Escitalopram—Ataxia—Carmustine—malignant glioma	0.000589	0.00302	CcSEcCtD
Escitalopram—CHRM1—brain—malignant glioma	0.000589	0.00872	CbGeAlD
Escitalopram—Face oedema—Temozolomide—malignant glioma	0.000585	0.00299	CcSEcCtD
Escitalopram—Liver function test abnormal—Carmustine—malignant glioma	0.000579	0.00296	CcSEcCtD
Escitalopram—Mood swings—Temozolomide—malignant glioma	0.000574	0.00294	CcSEcCtD
Escitalopram—Hypokalaemia—Carmustine—malignant glioma	0.000571	0.00292	CcSEcCtD
Escitalopram—Ataxia—Temozolomide—malignant glioma	0.00057	0.00292	CcSEcCtD
Escitalopram—Dehydration—Temozolomide—malignant glioma	0.000563	0.00288	CcSEcCtD
Escitalopram—Dry skin—Temozolomide—malignant glioma	0.000555	0.00284	CcSEcCtD
Escitalopram—Muscular weakness—Carmustine—malignant glioma	0.000553	0.00283	CcSEcCtD
Escitalopram—Hypokalaemia—Temozolomide—malignant glioma	0.000551	0.00282	CcSEcCtD
Escitalopram—Breast disorder—Temozolomide—malignant glioma	0.000547	0.0028	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000546	0.00279	CcSEcCtD
Escitalopram—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000546	0.00279	CcSEcCtD
Escitalopram—Dysphagia—Carmustine—malignant glioma	0.000542	0.00277	CcSEcCtD
Escitalopram—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000534	0.00273	CcSEcCtD
Escitalopram—Muscular weakness—Temozolomide—malignant glioma	0.000534	0.00273	CcSEcCtD
Escitalopram—Abdominal distension—Temozolomide—malignant glioma	0.000527	0.0027	CcSEcCtD
Escitalopram—Dysphagia—Temozolomide—malignant glioma	0.000524	0.00268	CcSEcCtD
Escitalopram—SLC6A2—brain—malignant glioma	0.00052	0.0077	CbGeAlD
Escitalopram—Pancytopenia—Carmustine—malignant glioma	0.000515	0.00263	CcSEcCtD
Escitalopram—Sweating increased—Temozolomide—malignant glioma	0.00051	0.00261	CcSEcCtD
Escitalopram—Bronchitis—Temozolomide—malignant glioma	0.000504	0.00258	CcSEcCtD
Escitalopram—Pancytopenia—Temozolomide—malignant glioma	0.000497	0.00254	CcSEcCtD
Escitalopram—Dysuria—Temozolomide—malignant glioma	0.00049	0.00251	CcSEcCtD
Escitalopram—Hyperglycaemia—Carmustine—malignant glioma	0.000489	0.0025	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000487	0.00249	CcSEcCtD
Escitalopram—Pneumonia—Carmustine—malignant glioma	0.000486	0.00249	CcSEcCtD
Escitalopram—ADRA1A—brain—malignant glioma	0.000484	0.00716	CbGeAlD
Escitalopram—Pollakiuria—Temozolomide—malignant glioma	0.000484	0.00248	CcSEcCtD
Escitalopram—Erectile dysfunction—Temozolomide—malignant glioma	0.000482	0.00247	CcSEcCtD
Escitalopram—Depression—Carmustine—malignant glioma	0.000482	0.00247	CcSEcCtD
Escitalopram—Photosensitivity reaction—Temozolomide—malignant glioma	0.000478	0.00245	CcSEcCtD
Escitalopram—Weight increased—Temozolomide—malignant glioma	0.000477	0.00244	CcSEcCtD
Escitalopram—Weight decreased—Temozolomide—malignant glioma	0.000474	0.00242	CcSEcCtD
Escitalopram—Neuropathy peripheral—Carmustine—malignant glioma	0.000474	0.00242	CcSEcCtD
Escitalopram—Hyperglycaemia—Temozolomide—malignant glioma	0.000472	0.00242	CcSEcCtD
Escitalopram—HRH1—central nervous system—malignant glioma	0.000472	0.00698	CbGeAlD
Escitalopram—Stomatitis—Carmustine—malignant glioma	0.000471	0.00241	CcSEcCtD
Escitalopram—Urinary tract infection—Carmustine—malignant glioma	0.00047	0.0024	CcSEcCtD
Escitalopram—Pneumonia—Temozolomide—malignant glioma	0.00047	0.0024	CcSEcCtD
Escitalopram—Infestation NOS—Temozolomide—malignant glioma	0.000467	0.00239	CcSEcCtD
Escitalopram—Infestation—Temozolomide—malignant glioma	0.000467	0.00239	CcSEcCtD
Escitalopram—Depression—Temozolomide—malignant glioma	0.000466	0.00238	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000463	0.00237	CcSEcCtD
Escitalopram—Neuropathy peripheral—Temozolomide—malignant glioma	0.000458	0.00234	CcSEcCtD
Escitalopram—Stomatitis—Temozolomide—malignant glioma	0.000455	0.00233	CcSEcCtD
Escitalopram—Urinary tract infection—Temozolomide—malignant glioma	0.000454	0.00232	CcSEcCtD
Escitalopram—Hepatobiliary disease—Temozolomide—malignant glioma	0.000442	0.00226	CcSEcCtD
Escitalopram—Sinusitis—Temozolomide—malignant glioma	0.000438	0.00224	CcSEcCtD
Escitalopram—Haemoglobin—Carmustine—malignant glioma	0.000436	0.00223	CcSEcCtD
Escitalopram—Haemorrhage—Carmustine—malignant glioma	0.000434	0.00222	CcSEcCtD
Escitalopram—Hypoaesthesia—Carmustine—malignant glioma	0.000432	0.00221	CcSEcCtD
Escitalopram—Hallucination—Carmustine—malignant glioma	0.000432	0.00221	CcSEcCtD
Escitalopram—Oedema peripheral—Carmustine—malignant glioma	0.000427	0.00219	CcSEcCtD
Escitalopram—Connective tissue disorder—Carmustine—malignant glioma	0.000426	0.00218	CcSEcCtD
Escitalopram—Haemoglobin—Temozolomide—malignant glioma	0.000421	0.00216	CcSEcCtD
Escitalopram—Hepatitis—Temozolomide—malignant glioma	0.000419	0.00215	CcSEcCtD
Escitalopram—Haemorrhage—Temozolomide—malignant glioma	0.000419	0.00215	CcSEcCtD
Escitalopram—Visual impairment—Carmustine—malignant glioma	0.000418	0.00214	CcSEcCtD
Escitalopram—Hypoaesthesia—Temozolomide—malignant glioma	0.000417	0.00213	CcSEcCtD
Escitalopram—Hallucination—Temozolomide—malignant glioma	0.000417	0.00213	CcSEcCtD
Escitalopram—Pharyngitis—Temozolomide—malignant glioma	0.000416	0.00213	CcSEcCtD
Escitalopram—Urinary tract disorder—Temozolomide—malignant glioma	0.000414	0.00212	CcSEcCtD
Escitalopram—Oedema peripheral—Temozolomide—malignant glioma	0.000413	0.00211	CcSEcCtD
Escitalopram—Connective tissue disorder—Temozolomide—malignant glioma	0.000412	0.00211	CcSEcCtD
Escitalopram—Urethral disorder—Temozolomide—malignant glioma	0.000411	0.0021	CcSEcCtD
Escitalopram—Eye disorder—Carmustine—malignant glioma	0.000405	0.00207	CcSEcCtD
Escitalopram—Visual impairment—Temozolomide—malignant glioma	0.000404	0.00207	CcSEcCtD
Escitalopram—Flushing—Carmustine—malignant glioma	0.000402	0.00206	CcSEcCtD
Escitalopram—Erythema multiforme—Temozolomide—malignant glioma	0.000396	0.00203	CcSEcCtD
Escitalopram—Eye disorder—Temozolomide—malignant glioma	0.000392	0.002	CcSEcCtD
Escitalopram—Tinnitus—Temozolomide—malignant glioma	0.000391	0.002	CcSEcCtD
Escitalopram—Cardiac disorder—Temozolomide—malignant glioma	0.000389	0.00199	CcSEcCtD
Escitalopram—Flushing—Temozolomide—malignant glioma	0.000389	0.00199	CcSEcCtD
Escitalopram—Arrhythmia—Carmustine—malignant glioma	0.000387	0.00198	CcSEcCtD
Escitalopram—Alopecia—Carmustine—malignant glioma	0.000383	0.00196	CcSEcCtD
Escitalopram—Angiopathy—Temozolomide—malignant glioma	0.00038	0.00195	CcSEcCtD
Escitalopram—Mental disorder—Carmustine—malignant glioma	0.00038	0.00194	CcSEcCtD
Escitalopram—Immune system disorder—Temozolomide—malignant glioma	0.000379	0.00194	CcSEcCtD
Escitalopram—Mediastinal disorder—Temozolomide—malignant glioma	0.000378	0.00193	CcSEcCtD
Escitalopram—Malnutrition—Carmustine—malignant glioma	0.000378	0.00193	CcSEcCtD
Escitalopram—Erythema—Carmustine—malignant glioma	0.000378	0.00193	CcSEcCtD
Escitalopram—Chills—Temozolomide—malignant glioma	0.000376	0.00192	CcSEcCtD
Escitalopram—HRH1—brain—malignant glioma	0.000374	0.00554	CbGeAlD
Escitalopram—Alopecia—Temozolomide—malignant glioma	0.00037	0.0019	CcSEcCtD
Escitalopram—Mental disorder—Temozolomide—malignant glioma	0.000367	0.00188	CcSEcCtD
Escitalopram—Back pain—Carmustine—malignant glioma	0.000365	0.00187	CcSEcCtD
Escitalopram—Erythema—Temozolomide—malignant glioma	0.000365	0.00187	CcSEcCtD
Escitalopram—Malnutrition—Temozolomide—malignant glioma	0.000365	0.00187	CcSEcCtD
Escitalopram—CYP3A4—central nervous system—malignant glioma	0.000365	0.0054	CbGeAlD
Escitalopram—CYP2D6—central nervous system—malignant glioma	0.000359	0.00531	CbGeAlD
Escitalopram—Dysgeusia—Temozolomide—malignant glioma	0.000357	0.00183	CcSEcCtD
Escitalopram—Vision blurred—Carmustine—malignant glioma	0.000356	0.00182	CcSEcCtD
Escitalopram—Tremor—Carmustine—malignant glioma	0.000354	0.00181	CcSEcCtD
Escitalopram—Back pain—Temozolomide—malignant glioma	0.000353	0.00181	CcSEcCtD
Escitalopram—CYP2D6—cerebellum—malignant glioma	0.000351	0.00519	CbGeAlD
Escitalopram—Anaemia—Carmustine—malignant glioma	0.000349	0.00179	CcSEcCtD
Escitalopram—Agitation—Carmustine—malignant glioma	0.000347	0.00178	CcSEcCtD
Escitalopram—Vision blurred—Temozolomide—malignant glioma	0.000344	0.00176	CcSEcCtD
Escitalopram—Tremor—Temozolomide—malignant glioma	0.000342	0.00175	CcSEcCtD
Escitalopram—Ill-defined disorder—Temozolomide—malignant glioma	0.000339	0.00173	CcSEcCtD
Escitalopram—Leukopenia—Carmustine—malignant glioma	0.000338	0.00173	CcSEcCtD
Escitalopram—Anaemia—Temozolomide—malignant glioma	0.000337	0.00173	CcSEcCtD
Escitalopram—Agitation—Temozolomide—malignant glioma	0.000335	0.00172	CcSEcCtD
Escitalopram—Angioedema—Temozolomide—malignant glioma	0.000333	0.00171	CcSEcCtD
Escitalopram—Malaise—Temozolomide—malignant glioma	0.000329	0.00168	CcSEcCtD
Escitalopram—Vertigo—Temozolomide—malignant glioma	0.000328	0.00168	CcSEcCtD
Escitalopram—Convulsion—Carmustine—malignant glioma	0.000327	0.00167	CcSEcCtD
Escitalopram—Leukopenia—Temozolomide—malignant glioma	0.000327	0.00167	CcSEcCtD
Escitalopram—Hypertension—Carmustine—malignant glioma	0.000326	0.00167	CcSEcCtD
Escitalopram—Palpitations—Temozolomide—malignant glioma	0.000322	0.00165	CcSEcCtD
Escitalopram—Chest pain—Carmustine—malignant glioma	0.000321	0.00165	CcSEcCtD
Escitalopram—Myalgia—Carmustine—malignant glioma	0.000321	0.00165	CcSEcCtD
Escitalopram—Anxiety—Carmustine—malignant glioma	0.00032	0.00164	CcSEcCtD
Escitalopram—Cough—Temozolomide—malignant glioma	0.000318	0.00163	CcSEcCtD
Escitalopram—Convulsion—Temozolomide—malignant glioma	0.000316	0.00162	CcSEcCtD
Escitalopram—Hypertension—Temozolomide—malignant glioma	0.000315	0.00161	CcSEcCtD
Escitalopram—Confusional state—Carmustine—malignant glioma	0.000311	0.00159	CcSEcCtD
Escitalopram—Myalgia—Temozolomide—malignant glioma	0.000311	0.00159	CcSEcCtD
Escitalopram—Arthralgia—Temozolomide—malignant glioma	0.000311	0.00159	CcSEcCtD
Escitalopram—Anxiety—Temozolomide—malignant glioma	0.00031	0.00158	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000308	0.00158	CcSEcCtD
Escitalopram—Oedema—Carmustine—malignant glioma	0.000308	0.00158	CcSEcCtD
Escitalopram—Discomfort—Temozolomide—malignant glioma	0.000307	0.00157	CcSEcCtD
Escitalopram—Infection—Carmustine—malignant glioma	0.000306	0.00157	CcSEcCtD
Escitalopram—Dry mouth—Temozolomide—malignant glioma	0.000304	0.00155	CcSEcCtD
Escitalopram—Thrombocytopenia—Carmustine—malignant glioma	0.000302	0.00154	CcSEcCtD
Escitalopram—Tachycardia—Carmustine—malignant glioma	0.000301	0.00154	CcSEcCtD
Escitalopram—Confusional state—Temozolomide—malignant glioma	0.0003	0.00154	CcSEcCtD
Escitalopram—Anaphylactic shock—Temozolomide—malignant glioma	0.000298	0.00152	CcSEcCtD
Escitalopram—Oedema—Temozolomide—malignant glioma	0.000298	0.00152	CcSEcCtD
Escitalopram—Infection—Temozolomide—malignant glioma	0.000296	0.00151	CcSEcCtD
Escitalopram—Anorexia—Carmustine—malignant glioma	0.000294	0.0015	CcSEcCtD
Escitalopram—Nervous system disorder—Temozolomide—malignant glioma	0.000292	0.00149	CcSEcCtD
Escitalopram—Thrombocytopenia—Temozolomide—malignant glioma	0.000292	0.00149	CcSEcCtD
Escitalopram—Skin disorder—Temozolomide—malignant glioma	0.000289	0.00148	CcSEcCtD
Escitalopram—Hypotension—Carmustine—malignant glioma	0.000288	0.00147	CcSEcCtD
Escitalopram—Hyperhidrosis—Temozolomide—malignant glioma	0.000288	0.00147	CcSEcCtD
Escitalopram—CYP2D6—brain—malignant glioma	0.000285	0.00422	CbGeAlD
Escitalopram—Anorexia—Temozolomide—malignant glioma	0.000284	0.00145	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000281	0.00144	CcSEcCtD
Escitalopram—Insomnia—Carmustine—malignant glioma	0.000279	0.00143	CcSEcCtD
Escitalopram—Paraesthesia—Carmustine—malignant glioma	0.000277	0.00142	CcSEcCtD
Escitalopram—Dyspnoea—Carmustine—malignant glioma	0.000275	0.00141	CcSEcCtD
Escitalopram—Somnolence—Carmustine—malignant glioma	0.000274	0.0014	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000271	0.00139	CcSEcCtD
Escitalopram—Insomnia—Temozolomide—malignant glioma	0.000269	0.00138	CcSEcCtD
Escitalopram—Decreased appetite—Carmustine—malignant glioma	0.000268	0.00137	CcSEcCtD
Escitalopram—Paraesthesia—Temozolomide—malignant glioma	0.000267	0.00137	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Carmustine—malignant glioma	0.000266	0.00136	CcSEcCtD
Escitalopram—Dyspnoea—Temozolomide—malignant glioma	0.000265	0.00136	CcSEcCtD
Escitalopram—Somnolence—Temozolomide—malignant glioma	0.000265	0.00135	CcSEcCtD
Escitalopram—Pain—Carmustine—malignant glioma	0.000263	0.00135	CcSEcCtD
Escitalopram—Constipation—Carmustine—malignant glioma	0.000263	0.00135	CcSEcCtD
Escitalopram—Dyspepsia—Temozolomide—malignant glioma	0.000262	0.00134	CcSEcCtD
Escitalopram—Decreased appetite—Temozolomide—malignant glioma	0.000259	0.00132	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000257	0.00132	CcSEcCtD
Escitalopram—Fatigue—Temozolomide—malignant glioma	0.000257	0.00131	CcSEcCtD
Escitalopram—Pain—Temozolomide—malignant glioma	0.000255	0.0013	CcSEcCtD
Escitalopram—Constipation—Temozolomide—malignant glioma	0.000255	0.0013	CcSEcCtD
Escitalopram—Feeling abnormal—Carmustine—malignant glioma	0.000254	0.0013	CcSEcCtD
Escitalopram—Gastrointestinal pain—Carmustine—malignant glioma	0.000252	0.00129	CcSEcCtD
Escitalopram—Feeling abnormal—Temozolomide—malignant glioma	0.000245	0.00126	CcSEcCtD
Escitalopram—Abdominal pain—Carmustine—malignant glioma	0.000244	0.00125	CcSEcCtD
Escitalopram—Body temperature increased—Carmustine—malignant glioma	0.000244	0.00125	CcSEcCtD
Escitalopram—Gastrointestinal pain—Temozolomide—malignant glioma	0.000243	0.00125	CcSEcCtD
Escitalopram—Urticaria—Temozolomide—malignant glioma	0.000237	0.00121	CcSEcCtD
Escitalopram—Body temperature increased—Temozolomide—malignant glioma	0.000235	0.0012	CcSEcCtD
Escitalopram—Abdominal pain—Temozolomide—malignant glioma	0.000235	0.0012	CcSEcCtD
Escitalopram—Hypersensitivity—Carmustine—malignant glioma	0.000227	0.00116	CcSEcCtD
Escitalopram—Asthenia—Carmustine—malignant glioma	0.000221	0.00113	CcSEcCtD
Escitalopram—Hypersensitivity—Temozolomide—malignant glioma	0.000219	0.00112	CcSEcCtD
Escitalopram—Asthenia—Temozolomide—malignant glioma	0.000214	0.00109	CcSEcCtD
Escitalopram—Diarrhoea—Carmustine—malignant glioma	0.000211	0.00108	CcSEcCtD
Escitalopram—Pruritus—Temozolomide—malignant glioma	0.000211	0.00108	CcSEcCtD
Escitalopram—Dizziness—Carmustine—malignant glioma	0.000204	0.00104	CcSEcCtD
Escitalopram—Diarrhoea—Temozolomide—malignant glioma	0.000204	0.00104	CcSEcCtD
Escitalopram—Dizziness—Temozolomide—malignant glioma	0.000197	0.00101	CcSEcCtD
Escitalopram—Vomiting—Carmustine—malignant glioma	0.000196	0.001	CcSEcCtD
Escitalopram—Rash—Carmustine—malignant glioma	0.000194	0.000994	CcSEcCtD
Escitalopram—Dermatitis—Carmustine—malignant glioma	0.000194	0.000993	CcSEcCtD
Escitalopram—Headache—Carmustine—malignant glioma	0.000193	0.000988	CcSEcCtD
Escitalopram—Vomiting—Temozolomide—malignant glioma	0.000189	0.000969	CcSEcCtD
Escitalopram—Rash—Temozolomide—malignant glioma	0.000188	0.000961	CcSEcCtD
Escitalopram—Dermatitis—Temozolomide—malignant glioma	0.000188	0.00096	CcSEcCtD
Escitalopram—Headache—Temozolomide—malignant glioma	0.000187	0.000955	CcSEcCtD
Escitalopram—Nausea—Carmustine—malignant glioma	0.000183	0.000937	CcSEcCtD
Escitalopram—Nausea—Temozolomide—malignant glioma	0.000177	0.000905	CcSEcCtD
Escitalopram—HTR2C—Signaling by GPCR—IL2—malignant glioma	1.11e-05	0.000195	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTK2—malignant glioma	1.11e-05	0.000195	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCL8—malignant glioma	1.11e-05	0.000195	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TERT—malignant glioma	1.11e-05	0.000194	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCL8—malignant glioma	1.11e-05	0.000194	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HES1—malignant glioma	1.1e-05	0.000192	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTK2—malignant glioma	1.1e-05	0.000192	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HES1—malignant glioma	1.09e-05	0.000192	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCL8—malignant glioma	1.09e-05	0.000191	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NCOR1—malignant glioma	1.09e-05	0.000191	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NCOR1—malignant glioma	1.09e-05	0.000191	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PDGFB—malignant glioma	1.08e-05	0.00019	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FGFR1—malignant glioma	1.08e-05	0.000189	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HES1—malignant glioma	1.08e-05	0.000189	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.08e-05	0.000189	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RAF1—malignant glioma	1.08e-05	0.000189	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RAF1—malignant glioma	1.07e-05	0.000188	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NCOR1—malignant glioma	1.07e-05	0.000188	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.07e-05	0.000187	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—IL2—malignant glioma	1.06e-05	0.000186	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HIF1A—malignant glioma	1.06e-05	0.000186	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—BCHE—malignant glioma	1.06e-05	0.000186	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—IL2—malignant glioma	1.06e-05	0.000186	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RAF1—malignant glioma	1.06e-05	0.000185	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CB—malignant glioma	1.05e-05	0.000184	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CB—malignant glioma	1.05e-05	0.000184	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC5A5—malignant glioma	1.05e-05	0.000183	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PDGFRA—malignant glioma	1.04e-05	0.000183	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—IL2—malignant glioma	1.04e-05	0.000183	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PDGFRA—malignant glioma	1.04e-05	0.000182	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—IDH1—malignant glioma	1.04e-05	0.000182	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CB—malignant glioma	1.03e-05	0.000181	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CAV1—malignant glioma	1.03e-05	0.00018	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PDGFRA—malignant glioma	1.02e-05	0.00018	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KDR—malignant glioma	1.01e-05	0.000178	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SPP1—malignant glioma	1.01e-05	0.000178	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SPP1—malignant glioma	1.01e-05	0.000177	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCL8—malignant glioma	1.01e-05	0.000177	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCL8—malignant glioma	1.01e-05	0.000176	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SPHK1—malignant glioma	1e-05	0.000176	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SPP1—malignant glioma	9.95e-06	0.000174	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCL8—malignant glioma	9.9e-06	0.000174	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP2C18—malignant glioma	9.83e-06	0.000172	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—F2—malignant glioma	9.76e-06	0.000171	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FN1—malignant glioma	9.76e-06	0.000171	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—BAD—malignant glioma	9.65e-06	0.000169	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL2—malignant glioma	9.65e-06	0.000169	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL2—malignant glioma	9.61e-06	0.000169	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TERT—malignant glioma	9.61e-06	0.000168	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TERT—malignant glioma	9.58e-06	0.000168	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	9.56e-06	0.000168	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL2—malignant glioma	9.47e-06	0.000166	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TERT—malignant glioma	9.43e-06	0.000165	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PDGFB—malignant glioma	9.38e-06	0.000164	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CD80—malignant glioma	9.36e-06	0.000164	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PDGFB—malignant glioma	9.35e-06	0.000164	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	9.34e-06	0.000164	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—APC—malignant glioma	9.34e-06	0.000164	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FGFR1—malignant glioma	9.33e-06	0.000164	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FGFR1—malignant glioma	9.3e-06	0.000163	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.3e-06	0.000163	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGF—malignant glioma	9.24e-06	0.000162	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PDGFB—malignant glioma	9.2e-06	0.000161	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HIF1A—malignant glioma	9.19e-06	0.000161	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTPN11—malignant glioma	9.18e-06	0.000161	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTP1—malignant glioma	9.17e-06	0.000161	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HIF1A—malignant glioma	9.16e-06	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FGFR1—malignant glioma	9.16e-06	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HIF1A—malignant glioma	9.02e-06	0.000158	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CAT—malignant glioma	8.92e-06	0.000156	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CAV1—malignant glioma	8.89e-06	0.000156	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CAV1—malignant glioma	8.86e-06	0.000155	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KDR—malignant glioma	8.79e-06	0.000154	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—BRAF—malignant glioma	8.78e-06	0.000154	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KDR—malignant glioma	8.76e-06	0.000154	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CAV1—malignant glioma	8.72e-06	0.000153	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KDR—malignant glioma	8.63e-06	0.000151	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT2—malignant glioma	8.55e-06	0.00015	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—malignant glioma	8.51e-06	0.000149	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FN1—malignant glioma	8.46e-06	0.000148	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—F2—malignant glioma	8.46e-06	0.000148	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FN1—malignant glioma	8.43e-06	0.000148	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—F2—malignant glioma	8.43e-06	0.000148	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—malignant glioma	8.43e-06	0.000148	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NCOR1—malignant glioma	8.42e-06	0.000148	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BAD—malignant glioma	8.36e-06	0.000147	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BAD—malignant glioma	8.33e-06	0.000146	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—F2—malignant glioma	8.3e-06	0.000146	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FN1—malignant glioma	8.3e-06	0.000146	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH1—malignant glioma	8.28e-06	0.000145	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH1—malignant glioma	8.25e-06	0.000145	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	8.21e-06	0.000144	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CAT—malignant glioma	8.2e-06	0.000144	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BAD—malignant glioma	8.2e-06	0.000144	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	8.14e-06	0.000143	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH1—malignant glioma	8.13e-06	0.000142	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CD80—malignant glioma	8.11e-06	0.000142	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CG—malignant glioma	8.1e-06	0.000142	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APC—malignant glioma	8.1e-06	0.000142	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CD80—malignant glioma	8.09e-06	0.000142	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APC—malignant glioma	8.07e-06	0.000141	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CG—malignant glioma	8.07e-06	0.000141	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—malignant glioma	8.04e-06	0.000141	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGF—malignant glioma	8e-06	0.00014	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGF—malignant glioma	7.98e-06	0.00014	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CD80—malignant glioma	7.96e-06	0.00014	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTPN11—malignant glioma	7.96e-06	0.000139	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—malignant glioma	7.95e-06	0.000139	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—malignant glioma	7.95e-06	0.000139	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APC—malignant glioma	7.95e-06	0.000139	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTPN11—malignant glioma	7.93e-06	0.000139	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FGF2—malignant glioma	7.87e-06	0.000138	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGF—malignant glioma	7.85e-06	0.000138	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTPN11—malignant glioma	7.81e-06	0.000137	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NCOR1—malignant glioma	7.75e-06	0.000136	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—malignant glioma	7.61e-06	0.000133	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—malignant glioma	7.59e-06	0.000133	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—malignant glioma	7.47e-06	0.000131	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS1—malignant glioma	7.45e-06	0.000131	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT2—malignant glioma	7.41e-06	0.00013	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	7.39e-06	0.00013	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT2—malignant glioma	7.38e-06	0.000129	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—malignant glioma	7.38e-06	0.000129	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MDM2—malignant glioma	7.36e-06	0.000129	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—malignant glioma	7.35e-06	0.000129	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAF1—malignant glioma	7.33e-06	0.000129	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT2—malignant glioma	7.27e-06	0.000127	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—malignant glioma	7.26e-06	0.000127	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—malignant glioma	7.24e-06	0.000127	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	7.16e-06	0.000126	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—malignant glioma	7.12e-06	0.000125	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—malignant glioma	7.1e-06	0.000124	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—malignant glioma	7.05e-06	0.000124	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—malignant glioma	7.03e-06	0.000123	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—malignant glioma	6.99e-06	0.000122	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—malignant glioma	6.97e-06	0.000122	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—malignant glioma	6.95e-06	0.000122	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BCHE—malignant glioma	6.93e-06	0.000121	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—malignant glioma	6.92e-06	0.000121	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—malignant glioma	6.88e-06	0.000121	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CAV1—malignant glioma	6.87e-06	0.00012	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC5A5—malignant glioma	6.84e-06	0.00012	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—malignant glioma	6.84e-06	0.00012	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FGF2—malignant glioma	6.82e-06	0.000119	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FGF2—malignant glioma	6.79e-06	0.000119	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FGF2—malignant glioma	6.69e-06	0.000117	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	6.65e-06	0.000117	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—malignant glioma	6.59e-06	0.000115	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—malignant glioma	6.58e-06	0.000115	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.56e-06	0.000115	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—malignant glioma	6.4e-06	0.000112	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—malignant glioma	6.38e-06	0.000112	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MDM2—malignant glioma	6.38e-06	0.000112	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MDM2—malignant glioma	6.36e-06	0.000111	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAF1—malignant glioma	6.36e-06	0.000111	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAF1—malignant glioma	6.33e-06	0.000111	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CAV1—malignant glioma	6.32e-06	0.000111	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—malignant glioma	6.29e-06	0.00011	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	6.28e-06	0.00011	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—malignant glioma	6.27e-06	0.00011	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MDM2—malignant glioma	6.26e-06	0.00011	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—malignant glioma	6.26e-06	0.00011	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAF1—malignant glioma	6.24e-06	0.000109	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.22e-06	0.000109	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—malignant glioma	6.2e-06	0.000109	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.19e-06	0.000108	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	6.18e-06	0.000108	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	6.17e-06	0.000108	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	6.09e-06	0.000107	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPARG—malignant glioma	6.04e-06	0.000106	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.04e-06	0.000106	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—malignant glioma	5.96e-06	0.000105	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—malignant glioma	5.94e-06	0.000104	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	5.85e-06	0.000103	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—malignant glioma	5.76e-06	0.000101	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.75e-06	0.000101	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	5.74e-06	0.000101	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—malignant glioma	5.71e-06	0.0001	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—malignant glioma	5.7e-06	9.99e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—malignant glioma	5.69e-06	9.97e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—malignant glioma	5.68e-06	9.96e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	5.65e-06	9.91e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—malignant glioma	5.6e-06	9.82e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—malignant glioma	5.59e-06	9.8e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.59e-06	9.8e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPARG—malignant glioma	5.55e-06	9.73e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.53e-06	9.7e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—malignant glioma	5.51e-06	9.66e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—malignant glioma	5.5e-06	9.64e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—malignant glioma	5.39e-06	9.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—malignant glioma	5.38e-06	9.42e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CAT—malignant glioma	5.36e-06	9.4e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—malignant glioma	5.36e-06	9.4e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—malignant glioma	5.34e-06	9.37e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—malignant glioma	5.29e-06	9.28e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—malignant glioma	5.26e-06	9.22e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—malignant glioma	5.23e-06	9.17e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—malignant glioma	5.21e-06	9.14e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—malignant glioma	5.14e-06	9.01e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	5.13e-06	9e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOR1—malignant glioma	5.07e-06	8.88e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.06e-06	8.87e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.03e-06	8.82e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—malignant glioma	4.84e-06	8.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—malignant glioma	4.83e-06	8.46e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—malignant glioma	4.79e-06	8.41e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—malignant glioma	4.79e-06	8.4e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—malignant glioma	4.78e-06	8.38e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	4.75e-06	8.33e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.75e-06	8.33e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—malignant glioma	4.75e-06	8.33e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—malignant glioma	4.71e-06	8.25e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—malignant glioma	4.46e-06	7.81e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—malignant glioma	4.44e-06	7.79e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.41e-06	7.73e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—malignant glioma	4.37e-06	7.66e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—malignant glioma	4.37e-06	7.66e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.37e-06	7.65e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—malignant glioma	4.36e-06	7.64e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—malignant glioma	4.34e-06	7.61e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—malignant glioma	4.28e-06	7.5e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—malignant glioma	4.22e-06	7.4e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—malignant glioma	4.14e-06	7.26e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CAV1—malignant glioma	4.13e-06	7.24e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—malignant glioma	4.12e-06	7.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—malignant glioma	4.1e-06	7.19e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—malignant glioma	4.04e-06	7.08e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—malignant glioma	3.81e-06	6.68e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—malignant glioma	3.78e-06	6.63e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	3.77e-06	6.61e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.76e-06	6.59e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	3.71e-06	6.51e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—malignant glioma	3.66e-06	6.41e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—malignant glioma	3.65e-06	6.39e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPARG—malignant glioma	3.63e-06	6.36e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—malignant glioma	3.59e-06	6.29e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.57e-06	6.25e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.31e-06	5.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—malignant glioma	3.09e-06	5.42e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—malignant glioma	3.08e-06	5.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—malignant glioma	3.03e-06	5.32e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.92e-06	5.12e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.88e-06	5.05e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—malignant glioma	2.86e-06	5.01e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.69e-06	4.71e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—malignant glioma	2.49e-06	4.37e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—malignant glioma	2.39e-06	4.18e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—malignant glioma	2.2e-06	3.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.76e-06	3.08e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—malignant glioma	1.44e-06	2.52e-05	CbGpPWpGaD
